UA76224C2 - Substituted 4-phenyl 4-[1h-imidazol-2-yl]-piperidine derivatives and use thereof as selective non-peptide delta-opioid agonists - Google Patents

Substituted 4-phenyl 4-[1h-imidazol-2-yl]-piperidine derivatives and use thereof as selective non-peptide delta-opioid agonists Download PDF

Info

Publication number: UA76224C2
Authority: UA; Ukraine
Prior art keywords: group; compounds; phenyl; reaction; compound
Prior art date: 2001-10-15

Application number

UA20040503667A

Other languages

English (en)

Ukrainian (uk)

Inventor

Frans Eduard Janssens

Joseph Elisabeth Leenaerts

Francisco Javi Fernandez-Gadea

Theo Frans Meert

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-15

Filing date

2002-10-10

Publication date

2006-07-17

2002-10-10 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2006-07-17 Publication of UA76224C2 publication Critical patent/UA76224C2/uk

Links

229940127450 Opioid Agonists Drugs 0.000 title abstract description 4
108090000765 processed proteins & peptides Proteins 0.000 title abstract description 4
GBANLFWFVPIRMO-UHFFFAOYSA-N 4-(1h-imidazol-2-yl)-4-phenylpiperidine Chemical class C1CNCCC1(C=1C=CC=CC=1)C1=NC=CN1 GBANLFWFVPIRMO-UHFFFAOYSA-N 0.000 title abstract 2
150000001875 compounds Chemical class 0.000 abstract description 118
208000002193 Pain Diseases 0.000 abstract description 29
125000000217 alkyl group Chemical group 0.000 abstract description 29
239000002253 acid Substances 0.000 abstract description 27
150000003839 salts Chemical class 0.000 abstract description 27
238000000034 method Methods 0.000 abstract description 21
229910052739 hydrogen Inorganic materials 0.000 abstract description 19
239000001257 hydrogen Substances 0.000 abstract description 17
238000002360 preparation method Methods 0.000 abstract description 16
125000003545 alkoxy group Chemical group 0.000 abstract description 14
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract description 8
125000004453 alkoxycarbonyl group Chemical group 0.000 abstract description 7
239000003814 drug Substances 0.000 abstract description 6
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract description 6
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract description 5
125000004183 alkoxy alkyl group Chemical group 0.000 abstract description 4
125000000815 N-oxide group Chemical group 0.000 abstract 1
238000006243 chemical reaction Methods 0.000 description 48
239000000203 mixture Substances 0.000 description 45
-1 cyano-benzoxazolyl Chemical group 0.000 description 38
239000002904 solvent Substances 0.000 description 30
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 26
102000005962 receptors Human genes 0.000 description 25
108020003175 receptors Proteins 0.000 description 25
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 23
239000002585 base Substances 0.000 description 22
239000000556 agonist Substances 0.000 description 18
125000004432 carbon atom Chemical group C* 0.000 description 17
150000003254 radicals Chemical class 0.000 description 16
239000000243 solution Substances 0.000 description 16
150000004820 halides Chemical class 0.000 description 14
239000010410 layer Substances 0.000 description 14
230000027455 binding Effects 0.000 description 13
125000001424 substituent group Chemical group 0.000 description 13
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
239000012044 organic layer Substances 0.000 description 11
239000011541 reaction mixture Substances 0.000 description 11
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 10
230000000694 effects Effects 0.000 description 9
150000002431 hydrogen Chemical class 0.000 description 9
210000004379 membrane Anatomy 0.000 description 9
239000012528 membrane Substances 0.000 description 9
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 9
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 9
238000010992 reflux Methods 0.000 description 9
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
238000009835 boiling Methods 0.000 description 8
125000004122 cyclic group Chemical group 0.000 description 8
239000012634 fragment Substances 0.000 description 8
125000003386 piperidinyl group Chemical group 0.000 description 8
102000003840 Opioid Receptors Human genes 0.000 description 7
108090000137 Opioid Receptors Proteins 0.000 description 7
238000004458 analytical method Methods 0.000 description 7
230000015572 biosynthetic process Effects 0.000 description 7
239000000872 buffer Substances 0.000 description 7
229910052799 carbon Inorganic materials 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
230000001404 mediated effect Effects 0.000 description 7
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 7
125000006684 polyhaloalkyl group Polymers 0.000 description 7
229930195734 saturated hydrocarbon Natural products 0.000 description 7
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
101100244562 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) oprD gene Proteins 0.000 description 6
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
125000003277 amino group Chemical group 0.000 description 6
239000005557 antagonist Substances 0.000 description 6
125000004429 atom Chemical group 0.000 description 6
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
210000004027 cell Anatomy 0.000 description 6
125000004093 cyano group Chemical group *C#N 0.000 description 6
108700023159 delta Opioid Receptors Proteins 0.000 description 6
102000048124 delta Opioid Receptors Human genes 0.000 description 6
239000003480 eluent Substances 0.000 description 6
125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 description 6
238000004519 manufacturing process Methods 0.000 description 6
208000004296 neuralgia Diseases 0.000 description 6
239000008194 pharmaceutical composition Substances 0.000 description 6
125000004076 pyridyl group Chemical group 0.000 description 6
239000000741 silica gel Substances 0.000 description 6
229910002027 silica gel Inorganic materials 0.000 description 6
229910052709 silver Inorganic materials 0.000 description 6
125000000335 thiazolyl group Chemical group 0.000 description 6
230000009471 action Effects 0.000 description 5
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
208000014674 injury Diseases 0.000 description 5
239000002287 radioligand Substances 0.000 description 5
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
239000004215 Carbon black (E152) Substances 0.000 description 4
150000007513 acids Chemical class 0.000 description 4
230000000202 analgesic effect Effects 0.000 description 4
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 4
WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 4
229910052796 boron Inorganic materials 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
229930195733 hydrocarbon Natural products 0.000 description 4
150000002430 hydrocarbons Chemical class 0.000 description 4
QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 4
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
102000051367 mu Opioid Receptors Human genes 0.000 description 4
208000021722 neuropathic pain Diseases 0.000 description 4
125000004193 piperazinyl group Chemical group 0.000 description 4
239000000047 product Substances 0.000 description 4
125000000168 pyrrolyl group Chemical group 0.000 description 4
230000002441 reversible effect Effects 0.000 description 4
238000003756 stirring Methods 0.000 description 4
108020001612 μ-opioid receptors Proteins 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
206010012735 Diarrhoea Diseases 0.000 description 3
241000282412 Homo Species 0.000 description 3
241000282414 Homo sapiens Species 0.000 description 3
206010021639 Incontinence Diseases 0.000 description 3
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
201000004681 Psoriasis Diseases 0.000 description 3
208000027418 Wounds and injury Diseases 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
230000009692 acute damage Effects 0.000 description 3
208000005298 acute pain Diseases 0.000 description 3
230000001270 agonistic effect Effects 0.000 description 3
125000003342 alkenyl group Chemical group 0.000 description 3
125000004414 alkyl thio group Chemical group 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
208000006673 asthma Diseases 0.000 description 3
239000012298 atmosphere Substances 0.000 description 3
125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 3
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
229910052794 bromium Inorganic materials 0.000 description 3
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 3
239000007810 chemical reaction solvent Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
229940125782 compound 2 Drugs 0.000 description 3
229940125898 compound 5 Drugs 0.000 description 3
230000006378 damage Effects 0.000 description 3
125000004663 dialkyl amino group Chemical group 0.000 description 3
125000004473 dialkylaminocarbonyl group Chemical group 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
201000006549 dyspepsia Diseases 0.000 description 3
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
201000000117 functional diarrhea Diseases 0.000 description 3
125000002541 furyl group Chemical group 0.000 description 3
125000002883 imidazolyl group Chemical group 0.000 description 3
238000011534 incubation Methods 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
208000002551 irritable bowel syndrome Diseases 0.000 description 3
102000048260 kappa Opioid Receptors Human genes 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000002609 medium Substances 0.000 description 3
125000002950 monocyclic group Chemical group 0.000 description 3
125000001624 naphthyl group Chemical group 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
125000003884 phenylalkyl group Chemical group 0.000 description 3
229940002612 prodrug Drugs 0.000 description 3
239000000651 prodrug Substances 0.000 description 3
208000037821 progressive disease Diseases 0.000 description 3
239000000018 receptor agonist Substances 0.000 description 3
229940044601 receptor agonist Drugs 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
229920006395 saturated elastomer Polymers 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000007858 starting material Substances 0.000 description 3
238000001356 surgical procedure Methods 0.000 description 3
208000011580 syndromic disease Diseases 0.000 description 3
108020001588 κ-opioid receptors Proteins 0.000 description 3
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
208000000094 Chronic Pain Diseases 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
QGWNDRXFNXRZMB-UUOKFMHZSA-N GDP Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O QGWNDRXFNXRZMB-UUOKFMHZSA-N 0.000 description 2
208000032612 Glial tumor Diseases 0.000 description 2
206010018338 Glioma Diseases 0.000 description 2
102000018997 Growth Hormone Human genes 0.000 description 2
108010051696 Growth Hormone Proteins 0.000 description 2
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
208000022559 Inflammatory bowel disease Diseases 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
206010036376 Postherpetic Neuralgia Diseases 0.000 description 2
LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
241000700159 Rattus Species 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
239000013543 active substance Substances 0.000 description 2
125000004448 alkyl carbonyl group Chemical group 0.000 description 2
125000005196 alkyl carbonyloxy group Chemical group 0.000 description 2
238000010171 animal model Methods 0.000 description 2
230000003042 antagnostic effect Effects 0.000 description 2
206010003246 arthritis Diseases 0.000 description 2
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 2
125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
229940098773 bovine serum albumin Drugs 0.000 description 2
239000011575 calcium Substances 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
239000000460 chlorine Substances 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
208000018912 cluster headache syndrome Diseases 0.000 description 2
210000001072 colon Anatomy 0.000 description 2
230000009137 competitive binding Effects 0.000 description 2
229940125904 compound 1 Drugs 0.000 description 2
238000011161 development Methods 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
238000001035 drying Methods 0.000 description 2
238000013504 emergency use authorization Methods 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
238000000605 extraction Methods 0.000 description 2
238000001914 filtration Methods 0.000 description 2
229910052731 fluorine Inorganic materials 0.000 description 2
239000011737 fluorine Substances 0.000 description 2
239000000122 growth hormone Substances 0.000 description 2
125000005842 heteroatom Chemical group 0.000 description 2
125000000623 heterocyclic group Chemical group 0.000 description 2
125000004464 hydroxyphenyl group Chemical group 0.000 description 2
125000002632 imidazolidinyl group Chemical group 0.000 description 2
125000002636 imidazolinyl group Chemical group 0.000 description 2
125000001041 indolyl group Chemical group 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
229910052740 iodine Inorganic materials 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
125000001786 isothiazolyl group Chemical group 0.000 description 2
125000000842 isoxazolyl group Chemical group 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
229940126601 medicinal product Drugs 0.000 description 2
229940095102 methyl benzoate Drugs 0.000 description 2
229960005181 morphine Drugs 0.000 description 2
125000002757 morpholinyl group Chemical group 0.000 description 2
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
DKJCUVXSBOMWAV-PCWWUVHHSA-N naltrindole Chemical compound N1([C@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CC2=C3[CH]C=CC=C3N=C25)O)CC1)O)CC1CC1 DKJCUVXSBOMWAV-PCWWUVHHSA-N 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
210000001331 nose Anatomy 0.000 description 2
150000007530 organic bases Chemical class 0.000 description 2
239000005416 organic matter Substances 0.000 description 2
125000004043 oxo group Chemical group O=* 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
125000003373 pyrazinyl group Chemical group 0.000 description 2
125000002755 pyrazolinyl group Chemical group 0.000 description 2
125000003226 pyrazolyl group Chemical group 0.000 description 2
125000002098 pyridazinyl group Chemical group 0.000 description 2
125000000714 pyrimidinyl group Chemical group 0.000 description 2
125000000719 pyrrolidinyl group Chemical group 0.000 description 2
125000001422 pyrrolinyl group Chemical group 0.000 description 2
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
230000000241 respiratory effect Effects 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
239000013049 sediment Substances 0.000 description 2
238000000926 separation method Methods 0.000 description 2
210000002460 smooth muscle Anatomy 0.000 description 2
210000004872 soft tissue Anatomy 0.000 description 2
239000012453 solvate Substances 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
239000000725 suspension Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
125000001544 thienyl group Chemical group 0.000 description 2
125000004149 thio group Chemical group *S* 0.000 description 2
125000004568 thiomorpholinyl group Chemical group 0.000 description 2
230000000451 tissue damage Effects 0.000 description 2
231100000827 tissue damage Toxicity 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
230000008733 trauma Effects 0.000 description 2
230000001562 ulcerogenic effect Effects 0.000 description 2
QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
AEMOLEFTQBMNLQ-SYJWYVCOSA-N (2s,3s,4s,5s,6r)-3,4,5,6-tetrahydroxyoxane-2-carboxylic acid Chemical compound O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-SYJWYVCOSA-N 0.000 description 1
QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical group C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 description 1
SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
ARYICIJWHSZXTO-UHFFFAOYSA-N 1-benzylpiperidine-4-carboxamide Chemical compound C1CC(C(=O)N)CCN1CC1=CC=CC=C1 ARYICIJWHSZXTO-UHFFFAOYSA-N 0.000 description 1
KROJTROJEIETIK-UHFFFAOYSA-N 1-methyl-4-phenylpiperidine-4-carbonyl chloride Chemical class C1CN(C)CCC1(C(Cl)=O)C1=CC=CC=C1 KROJTROJEIETIK-UHFFFAOYSA-N 0.000 description 1
OARGFWQSVACNCO-UHFFFAOYSA-N 1-oxidoquinoxalin-1-ium Chemical group C1=CC=C2[N+]([O-])=CC=NC2=C1 OARGFWQSVACNCO-UHFFFAOYSA-N 0.000 description 1
KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
QKWWDTYDYOFRJL-UHFFFAOYSA-N 2,2-dimethoxyethanamine Chemical compound COC(CN)OC QKWWDTYDYOFRJL-UHFFFAOYSA-N 0.000 description 1
WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
IUVCFHHAEHNCFT-INIZCTEOSA-N 2-[(1s)-1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=C(F)C(OC(C)C)=CC=C1C(C1=C(N)N=CN=C11)=NN1[C@@H](C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC(F)=CC=C2O1 IUVCFHHAEHNCFT-INIZCTEOSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
VQMPTVQCADWACQ-UHFFFAOYSA-N 3-methylpentan-3-amine Chemical compound CCC(C)(N)CC VQMPTVQCADWACQ-UHFFFAOYSA-N 0.000 description 1
WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
206010001497 Agitation Diseases 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
241000219495 Betulaceae Species 0.000 description 1
ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
241000283725 Bos Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000722731 Carex Species 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
208000032131 Diabetic Neuropathies Diseases 0.000 description 1
QAHFOPIILNICLA-UHFFFAOYSA-N Diphenamid Chemical compound C=1C=CC=CC=1C(C(=O)N(C)C)C1=CC=CC=C1 QAHFOPIILNICLA-UHFFFAOYSA-N 0.000 description 1
229920006056 Dymid® Polymers 0.000 description 1
102100037807 GATOR complex protein MIOS Human genes 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
101000950705 Homo sapiens GATOR complex protein MIOS Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
208000029462 Immunodeficiency disease Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
241001547328 Kerya Species 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical class [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical class [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
206010029333 Neurosis Diseases 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical class [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
241000288906 Primates Species 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
241000159610 Roya <green alga> Species 0.000 description 1
229910006898 SnSi Inorganic materials 0.000 description 1
241000657469 Spermacoce capitata Species 0.000 description 1
101000720079 Stichodactyla helianthus DELTA-stichotoxin-She4a Proteins 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
241001122767 Theaceae Species 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
YFPXKFCSFLHFNR-UHFFFAOYSA-N [2-(hydroxymethyl)phenyl] acetate Chemical compound CC(=O)OC1=CC=CC=C1CO YFPXKFCSFLHFNR-UHFFFAOYSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
VSMZEBRCBDBBSF-UHFFFAOYSA-N acetic acid propane-1,2-diol Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)CO VSMZEBRCBDBBSF-UHFFFAOYSA-N 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
150000001263 acyl chlorides Chemical class 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
239000003513 alkali Substances 0.000 description 1
125000006177 alkyl benzyl group Chemical group 0.000 description 1
150000001350 alkyl halides Chemical class 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
229960004909 aminosalicylic acid Drugs 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
230000000954 anitussive effect Effects 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000001142 anti-diarrhea Effects 0.000 description 1
230000001387 anti-histamine Effects 0.000 description 1
230000003502 anti-nociceptive effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000012984 antibiotic solution Substances 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
238000003556 assay Methods 0.000 description 1
JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
125000005605 benzo group Chemical group 0.000 description 1
125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
DKIVQMBUHVYDFC-IWRYZOJTSA-N binaltorphimine Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3C=5N(C=6[C@@H]7OC=8C(O)=CC=C9C[C@@H]%10[C@]([C@@]7(CCN%10CC7CC7)C9=8)(O)CC=6C=5C[C@]2(O)[C@]34CC1)C)CC1CC1 DKIVQMBUHVYDFC-IWRYZOJTSA-N 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
125000002837 carbocyclic group Chemical group 0.000 description 1
229910002091 carbon monoxide Inorganic materials 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
WBLIXGSTEMXDSM-UHFFFAOYSA-N chloromethane Chemical compound Cl[CH2] WBLIXGSTEMXDSM-UHFFFAOYSA-N 0.000 description 1
230000001713 cholinergic effect Effects 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
230000000112 colonic effect Effects 0.000 description 1
238000002485 combustion reaction Methods 0.000 description 1
238000004891 communication Methods 0.000 description 1
230000006957 competitive inhibition Effects 0.000 description 1
229940125773 compound 10 Drugs 0.000 description 1
229940125797 compound 12 Drugs 0.000 description 1
ONCCWDRMOZMNSM-FBCQKBJTSA-N compound Z Chemical compound N1=C2C(=O)NC(N)=NC2=NC=C1C(=O)[C@H]1OP(O)(=O)OC[C@H]1O ONCCWDRMOZMNSM-FBCQKBJTSA-N 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
INUNXTSAACVKJS-OAQYLSRUSA-N dextromoramide Chemical compound C([C@@H](C)C(C(=O)N1CCCC1)(C=1C=CC=CC=1)C=1C=CC=CC=1)N1CCOCC1 INUNXTSAACVKJS-OAQYLSRUSA-N 0.000 description 1
229960003701 dextromoramide Drugs 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
239000000032 diagnostic agent Substances 0.000 description 1
229940039227 diagnostic agent Drugs 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
229960003638 dopamine Drugs 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000010828 elution Methods 0.000 description 1
125000002587 enol group Chemical group 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
150000003947 ethylamines Chemical class 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
210000000887 face Anatomy 0.000 description 1
230000001815 facial effect Effects 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
239000006260 foam Substances 0.000 description 1
238000001640 fractional crystallisation Methods 0.000 description 1
235000011389 fruit/vegetable juice Nutrition 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
238000010230 functional analysis Methods 0.000 description 1
230000004927 fusion Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
QGWNDRXFNXRZMB-UHFFFAOYSA-N guanidine diphosphate Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O QGWNDRXFNXRZMB-UHFFFAOYSA-N 0.000 description 1
125000005067 haloformyl group Chemical group 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
238000005984 hydrogenation reaction Methods 0.000 description 1
125000002768 hydroxyalkyl group Chemical group 0.000 description 1
125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
230000007813 immunodeficiency Effects 0.000 description 1
230000003308 immunostimulating effect Effects 0.000 description 1
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
239000011261 inert gas Substances 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
208000028774 intestinal disease Diseases 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
239000002085 irritant Substances 0.000 description 1
231100000021 irritant Toxicity 0.000 description 1
238000002955 isolation Methods 0.000 description 1
ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
125000000468 ketone group Chemical group 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000003446 ligand Substances 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
GPSDUZXPYCFOSQ-UHFFFAOYSA-M m-toluate Chemical compound CC1=CC=CC(C([O-])=O)=C1 GPSDUZXPYCFOSQ-UHFFFAOYSA-M 0.000 description 1
239000011777 magnesium Chemical class 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
229960002510 mandelic acid Drugs 0.000 description 1
239000000463 material Substances 0.000 description 1
230000008018 melting Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
RPZHFKHTXCZXQV-UHFFFAOYSA-N mercury(I) oxide Inorganic materials O1[Hg][Hg]1 RPZHFKHTXCZXQV-UHFFFAOYSA-N 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
ATFKBWNEVZUSKC-UHFFFAOYSA-N methyl 2-isocyanatobenzoate Chemical compound COC(=O)C1=CC=CC=C1N=C=O ATFKBWNEVZUSKC-UHFFFAOYSA-N 0.000 description 1
NLWBJPPMPLPZIE-UHFFFAOYSA-N methyl 4-(bromomethyl)benzoate Chemical compound COC(=O)C1=CC=C(CBr)C=C1 NLWBJPPMPLPZIE-UHFFFAOYSA-N 0.000 description 1
125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
230000004899 motility Effects 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
229960004127 naloxone Drugs 0.000 description 1
230000003533 narcotic effect Effects 0.000 description 1
230000010807 negative regulation of binding Effects 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
230000002981 neuropathic effect Effects 0.000 description 1
208000015238 neurotic disease Diseases 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
229910052759 nickel Inorganic materials 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
230000002536 noncholinergic effect Effects 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
239000003921 oil Substances 0.000 description 1
239000003402 opiate agonist Substances 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
230000037361 pathway Effects 0.000 description 1
235000019371 penicillin G benzathine Nutrition 0.000 description 1
VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
208000033808 peripheral neuropathy Diseases 0.000 description 1
DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical compound O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
150000004885 piperazines Chemical class 0.000 description 1
XZDAPMNJXYGRPD-UHFFFAOYSA-N piperidine-1-carboximidamide;dihydrochloride Chemical compound Cl.Cl.NC(=N)N1CCCCC1 XZDAPMNJXYGRPD-UHFFFAOYSA-N 0.000 description 1
FLKRMXAWABTWSH-UHFFFAOYSA-N piperidine-1-sulfonamide Chemical compound NS(=O)(=O)N1CCCCC1 FLKRMXAWABTWSH-UHFFFAOYSA-N 0.000 description 1
150000003053 piperidines Chemical class 0.000 description 1
230000012354 positive regulation of binding Effects 0.000 description 1
239000011591 potassium Chemical class 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
238000011533 pre-incubation Methods 0.000 description 1
238000002953 preparative HPLC Methods 0.000 description 1
238000004237 preparative chromatography Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
125000003072 pyrazolidinyl group Chemical group 0.000 description 1
229940107700 pyruvic acid Drugs 0.000 description 1
239000001397 quillaja saponaria molina bark Substances 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
239000000376 reactant Substances 0.000 description 1
239000012429 reaction media Substances 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000004202 respiratory function Effects 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
208000023504 respiratory system disease Diseases 0.000 description 1
239000011435 rock Substances 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
229930182490 saponin Natural products 0.000 description 1
150000007949 saponins Chemical class 0.000 description 1
238000003345 scintillation counting Methods 0.000 description 1
238000010956 selective crystallization Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
238000009958 sewing Methods 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
230000008054 signal transmission Effects 0.000 description 1
239000011734 sodium Chemical class 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
241000894007 species Species 0.000 description 1
NYKCGQQJNVPOLU-ONTIZHBOSA-N spiradoline Chemical compound C([C@@H]([C@H](C1)N2CCCC2)N(C)C(=O)CC=2C=C(Cl)C(Cl)=CC=2)C[C@]21CCCO2 NYKCGQQJNVPOLU-ONTIZHBOSA-N 0.000 description 1
229950006495 spiradoline Drugs 0.000 description 1
SETMGIIITGNLAS-UHFFFAOYSA-N spizofurone Chemical compound O=C1C2=CC(C(=O)C)=CC=C2OC21CC2 SETMGIIITGNLAS-UHFFFAOYSA-N 0.000 description 1
229950001870 spizofurone Drugs 0.000 description 1
230000000707 stereoselective effect Effects 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
229960002385 streptomycin sulfate Drugs 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
229940066771 systemic antihistamines piperazine derivative Drugs 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
238000003419 tautomerization reaction Methods 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000012360 testing method Methods 0.000 description 1
125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000001256 tonic effect Effects 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
230000026683 transduction Effects 0.000 description 1
238000010361 transduction Methods 0.000 description 1
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
206010044652 trigeminal neuralgia Diseases 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Nutrition Science (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

UA20040503667A 2001-10-15 2002-10-10 Substituted 4-phenyl 4-[1h-imidazol-2-yl]-piperidine derivatives and use thereof as selective non-peptide delta-opioid agonists UA76224C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP01203926		2001-10-15
PCT/EP2002/011372 WO2003033486A1 (fr)	2001-10-15	2002-10-10	Nouveau derive 4-phenyl-4-[1h-imidazol-2-yl]-piperidine et leur utilisation en tant qu'agoniste selectif non peptidique des recepteurs delta opioides

Publications (1)

Publication Number	Publication Date
UA76224C2 true UA76224C2 (en)	2006-07-17

Family

ID=8181080

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA20040503667A UA76224C2 (en)	2001-10-15	2002-10-10	Substituted 4-phenyl 4-[1h-imidazol-2-yl]-piperidine derivatives and use thereof as selective non-peptide delta-opioid agonists

Country Status (26)

Country	Link
US (2)	US7282508B2 (fr)
EP (1)	EP1438304B1 (fr)
JP (1)	JP4417108B2 (fr)
KR (1)	KR100898562B1 (fr)
CN (1)	CN100354273C (fr)
AR (1)	AR037506A1 (fr)
AT (1)	ATE347549T1 (fr)
AU (1)	AU2002346994B2 (fr)
BR (1)	BR0213327A (fr)
CA (1)	CA2462953C (fr)
CY (1)	CY1106356T1 (fr)
DE (1)	DE60216627T2 (fr)
EA (1)	EA006507B1 (fr)
ES (1)	ES2278065T3 (fr)
HR (1)	HRP20040324A2 (fr)
HU (1)	HUP0600447A3 (fr)
IL (2)	IL161348A0 (fr)
MX (1)	MXPA04003479A (fr)
MY (1)	MY137356A (fr)
NO (1)	NO327602B1 (fr)
NZ (1)	NZ531679A (fr)
PL (1)	PL367967A1 (fr)
PT (1)	PT1438304E (fr)
UA (1)	UA76224C2 (fr)
WO (1)	WO2003033486A1 (fr)
ZA (1)	ZA200402818B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2462374C (fr) *	2001-10-15	2011-01-18	Janssen Pharmaceutica N.V.	Derives de 4-phenyl-4-(1h-imidazol-2-yl)-piperidine substituee utiles pour reduire les lesions ischemiques
TW200403058A (en) *	2002-04-19	2004-03-01	Bristol Myers Squibb Co	Heterocyclo inhibitors of potassium channel function
CA2484936A1 (fr)	2002-05-08	2004-05-21	Neurogen Corporation	Imidazolylmethyl pyridine substituee et derives de pyrazine: les ligands des recepteurs gaba<sb>a</sb>
US20060128752A1 (en) *	2002-07-03	2006-06-15	Giuseppe Alvaro	Chemical compounds
CL2004000754A1 (es) *	2003-04-11	2005-02-25	Janssen Pharmaceutica Nv	Uso de compuestos derivados de 4-fenil-4-(1h-imidazol-2-il)piperidina, como agonistas delta-opioides no peptidicos, para preparar un medicamento util en prevenir o tratar trastornos del sistema nervioso central.
KR20140015122A (ko)	2003-10-01	2014-02-06	아돌로 코포레이션	스피로시클릭 헤테로시클릭 유도체 및 이의 사용 방법
KR101166342B1 (ko) *	2004-03-15	2012-07-18	얀센 파마슈티카 엔.브이.	아편계 약물 수용체 조절자로서의 신규의 화합물
AU2013205089B2 (en) *	2004-03-15	2013-12-19	Janssen Pharmaceutica, N.V.	Novel compounds as opioid receptor modulators
US7598261B2 (en)	2005-03-31	2009-10-06	Adolor Corporation	Spirocyclic heterocyclic derivatives and methods of their use
US7576207B2 (en)	2006-04-06	2009-08-18	Adolor Corporation	Spirocyclic heterocyclic derivatives and methods of their use
WO2008033299A2 (fr)	2006-09-12	2008-03-20	Adolor Corporation	Méthodes d'amélioration de la fonction cognitive
IT1396951B1 (it)	2009-12-18	2012-12-20	Neuroscienze Pharmaness S C A R L	Composti farmaceutici
US20170119786A1 (en)	2011-03-08	2017-05-04	3-V Biosciences, Inc.	Heterocyclic modulators of lipid synthesis
US9675587B2 (en)	2013-03-14	2017-06-13	Allergan Holdings Unlimited Company	Opioid receptor modulator dosage formulations
TWI652264B (zh) *	2013-09-26	2019-03-01	東麗股份有限公司	Cyclic amine derivatives and their medical uses
CN111417394B (zh)	2017-10-19	2023-11-07	帝人制药株式会社	苯并咪唑衍生物及其用途
JPWO2022250108A1 (fr) *	2021-05-26	2022-12-01

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2985322B2 (ja)	1991-03-01	1999-11-29	東レ株式会社	イソキノリン誘導体およびその医薬用途
US5354863A (en)	1992-01-21	1994-10-11	G. D. Searle & Co.	Opioid agonist compounds
GB9202238D0 (en)	1992-02-03	1992-03-18	Wellcome Found	Compounds
DE69430373T2 (de)	1993-08-06	2002-12-12	Smithkline Beecham S.P.A., Baranzate Di Bollate	Hydroisochinolinderivate
US5618934A (en)	1994-05-17	1997-04-08	Merck & Co., Inc.	Boronic acid compound
AU4458996A (en)	1995-01-20	1996-08-07	Nippon Shinyaku Co. Ltd.	Ethylamine derivatives and drugs
IT1307327B1 (it)	1995-09-12	2001-10-30	Smithkline Beecham Spa	Derivati idroisochinolinici sostituiti
TW548271B (en)	1996-12-20	2003-08-21	Astra Pharma Inc	Novel piperidine derivatives having an exocyclic double bond with analgesic effects
SE9604786D0 (sv)	1996-12-20	1996-12-20	Astra Pharma Inc	New compounds
DE19805370A1 (de)	1997-03-14	1998-09-17	Gruenenthal Gmbh	Substituierte Aminoverbindungen und ihre Verwendung als analgetisch wirksame Substanzen
GB9709972D0 (en)	1997-05-19	1997-07-09	Pfizer Ltd	Tetrazoles
BR9916371A (pt) *	1998-12-19	2001-09-18	Janssen Pharmaceutica Nv	Composto de espiro anti-histamìnico
EP1038872A1 (fr) *	1999-02-22	2000-09-27	Pfizer Products Inc.	Dérivés de 4-phényl-4-hétéroarylpiperdine comme ligands des récepteurs opioides
JP2005231995A (ja)	1999-12-22	2005-09-02	Meiji Seika Kaisha Ltd	オピオイドδ受容体アゴニスト／アンタゴニストとして有用なスピロ化合物

2002
- 2002-10-10 JP JP2003536226A patent/JP4417108B2/ja not_active Expired - Fee Related
- 2002-10-10 US US10/491,379 patent/US7282508B2/en not_active Expired - Fee Related
- 2002-10-10 MX MXPA04003479A patent/MXPA04003479A/es active IP Right Grant
- 2002-10-10 DE DE60216627T patent/DE60216627T2/de not_active Expired - Lifetime
- 2002-10-10 PT PT02782881T patent/PT1438304E/pt unknown
- 2002-10-10 EA EA200400545A patent/EA006507B1/ru not_active IP Right Cessation
- 2002-10-10 UA UA20040503667A patent/UA76224C2/uk unknown
- 2002-10-10 ES ES02782881T patent/ES2278065T3/es not_active Expired - Lifetime
- 2002-10-10 AT AT02782881T patent/ATE347549T1/de active
- 2002-10-10 CA CA2462953A patent/CA2462953C/fr not_active Expired - Lifetime
- 2002-10-10 PL PL02367967A patent/PL367967A1/xx unknown
- 2002-10-10 HR HR20040324A patent/HRP20040324A2/xx not_active Application Discontinuation
- 2002-10-10 BR BR0213327-0A patent/BR0213327A/pt not_active IP Right Cessation
- 2002-10-10 WO PCT/EP2002/011372 patent/WO2003033486A1/fr not_active Ceased
- 2002-10-10 CN CNB028203275A patent/CN100354273C/zh not_active Expired - Fee Related
- 2002-10-10 KR KR1020047002381A patent/KR100898562B1/ko not_active Expired - Fee Related
- 2002-10-10 HU HU0600447A patent/HUP0600447A3/hu unknown
- 2002-10-10 EP EP02782881A patent/EP1438304B1/fr not_active Expired - Lifetime
- 2002-10-10 NZ NZ531679A patent/NZ531679A/en not_active IP Right Cessation
- 2002-10-10 IL IL16134802A patent/IL161348A0/xx unknown
- 2002-10-10 AU AU2002346994A patent/AU2002346994B2/en not_active Ceased
- 2002-10-11 MY MYPI20023800A patent/MY137356A/en unknown
- 2002-10-11 AR ARP020103837A patent/AR037506A1/es unknown
2004
- 2004-04-13 IL IL161348A patent/IL161348A/en not_active IP Right Cessation
- 2004-04-13 ZA ZA2004/02818A patent/ZA200402818B/en unknown
- 2004-04-22 NO NO20041666A patent/NO327602B1/no not_active IP Right Cessation
2007
- 2007-03-06 CY CY20071100311T patent/CY1106356T1/el unknown
- 2007-05-25 US US11/753,830 patent/US20080096925A1/en not_active Abandoned

Also Published As

Publication number	Publication date
ZA200402818B (en)	2005-06-29
NZ531679A (en)	2005-02-25
BR0213327A (pt)	2004-10-13
HUP0600447A2 (en)	2006-09-28
JP2005505625A (ja)	2005-02-24
ES2278065T3 (es)	2007-08-01
IL161348A (en)	2010-11-30
DE60216627T2 (de)	2007-09-20
DE60216627D1 (de)	2007-01-18
KR100898562B1 (ko)	2009-05-20
CN100354273C (zh)	2007-12-12
JP4417108B2 (ja)	2010-02-17
US20040260096A1 (en)	2004-12-23
NO327602B1 (no)	2009-08-31
MY137356A (en)	2009-01-30
US7282508B2 (en)	2007-10-16
CA2462953C (fr)	2011-01-04
PL367967A1 (en)	2005-03-07
NO20041666L (no)	2004-04-22
IL161348A0 (en)	2004-09-27
EA200400545A1 (ru)	2004-08-26
KR20050035121A (ko)	2005-04-15
HRP20040324A2 (en)	2005-04-30
CY1106356T1 (el)	2011-10-12
EP1438304B1 (fr)	2006-12-06
EP1438304A1 (fr)	2004-07-21
AU2002346994B2 (en)	2007-09-06
MXPA04003479A (es)	2004-07-30
EA006507B1 (ru)	2005-12-29
CA2462953A1 (fr)	2003-04-24
PT1438304E (pt)	2007-03-30
US20080096925A1 (en)	2008-04-24
AR037506A1 (es)	2004-11-17
WO2003033486A1 (fr)	2003-04-24
ATE347549T1 (de)	2006-12-15
HUP0600447A3 (en)	2008-03-28
CN1568321A (zh)	2005-01-19

Publication	Publication Date	Title
RU2140921C1 (ru)	1999-11-10	Непептидные антагонисты рецепторов тахикинина
AU2006215080B2 (en)	2011-03-10	Pyridyl non-aromatic nitrogenated heterocyclic-1-carboxylate ester derivative
US7329673B2 (en)	2008-02-12	Acylated spiropiperidine derivatives as melanocortin-4 receptor agonists
US7229996B2 (en)	2007-06-12	Rifamycin derivatives
EP0930298B1 (fr)	2002-12-18	Derives de piperidine fluores a disubstitution en position 1,4
US5565568A (en)	1996-10-15	2-acylaminopropanamides as tachykinin receptor antagonists
EP1204665B1 (fr)	2009-01-07	Antagonistes du recepteur de chimiokine et procedes d'utilisation associes
HRP20020926A2 (en)	2005-02-28	Arylmethylamine derivatives for use as tryptase inhibitors
US20080096925A1 (en)	2008-04-24	Novel Substituted 4-Phenyl-4[H-Imidazol-2-YL]-Piperidine Derivatived And Their Use As Selective Non-Peptide Delta Opioid Agonists
CN102325754B (zh)	2014-03-12	含杂原子的环状化合物
JP2002501898A (ja)	2002-01-22	ケモカイン受容体活性の環状アミン調節剤
CZ20024146A3 (cs)	2003-05-14	Nové sloučeniny
EP0686629A2 (fr)	1995-12-13	Antagonistes des récepteurs de tachycinine cyclohexyliques
US5814636A (en)	1998-09-29	Compounds with platelet aggregation inhibitor activity
AU2757400A (en)	2000-08-25	Sulfamato hydroxamic acid metalloprotease inhibitor
TW202346289A (zh)	2023-12-01	作為ｇｌｐ—１ｒ促效劑的化合物
US9751847B2 (en)	2017-09-05	Methods and compositions related to neuroactive thiazoline compounds
JP2002505685A (ja)	2002-02-19	α１ａアドレナリン受容体拮抗薬
EP3929188A1 (fr)	2021-12-29	Composé antagoniste de pd-l1
EP1448566B1 (fr)	2006-03-15	Antagonistes des recepteurs de la chimiokine et methodes d'utilisation de ces antagonistes
US20030008861A1 (en)	2003-01-09	N-arylsulfonyl aza-bicyclic derivatives as potent cell adhesion inhibitors
EP1421070B1 (fr)	2008-11-26	Nouveaux derives de piperidinyle, utilises en tant que modulateurs de l'activite d'un recepteur de chimiokine
JP2007197428A (ja)	2007-08-09	医薬組成物
KR20080089461A (ko)	2008-10-06	무스카린 수용체 길항제
JP3657982B6 (ja)	2005-08-24	非ペプチド性タキキニン受容体拮抗物質